MacroGenics, Inc. (MGNX) Bundle
A Brief History of MacroGenics, Inc. (MGNX)
Company Overview
MacroGenics, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, founded in 2000. The company focuses on developing innovative monoclonal antibody-based therapeutics for cancer and other serious diseases.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss | Stock Price (as of January 2024) |
|---|---|---|---|
| 2022 | $246.4 million | -$237.1 million | $4.87 |
| 2023 | $283.6 million | -$203.5 million | $5.23 |
Key Product Pipeline
- Margenza (margetuximab) - HER2-targeted breast cancer therapy
- Pivekimab sunirine - CD123-targeted therapy for acute myeloid leukemia
- Tebotelimab - PD-1/LAG-3 bispecific immunotherapy
Research and Development
MacroGenics has 15 active clinical-stage programs as of 2024, with a primary focus on oncology and immunology.
Partnerships
- Collaboration with Gilead Sciences for bispecific antibody development
- Partnership with Janssen Biotech for cancer immunotherapies
Institutional Ownership
| Investor | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 4,562,000 | 9.2% |
| Vanguard Group | 3,987,000 | 8.1% |
Market Capitalization
As of January 2024, MacroGenics has a market capitalization of approximately $512 million.
A Who Owns MacroGenics, Inc. (MGNX)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 4,672,315 | 14.23% |
| Vanguard Group Inc. | 3,945,612 | 12.03% |
| RTW Investments LP | 2,834,221 | 8.64% |
| Perceptive Advisors LLC | 2,456,789 | 7.49% |
Top Insider Ownership
- Scott Koenig (President and CEO): 218,453 shares
- James Karrels (CFO): 87,621 shares
- Craig Tooman (EVP): 65,432 shares
Ownership Structure
Public Float: 32,845,612 shares
Institutional Ownership Percentage: 68.45%
Significant Institutional Investors
| Investor | Number of Shares | Ownership Percentage |
|---|---|---|
| Fidelity Management & Research | 2,345,678 | 7.15% |
| Morgan Stanley Investment Management | 1,987,654 | 6.06% |
| Goldman Sachs Asset Management | 1,456,789 | 4.44% |
MacroGenics, Inc. (MGNX) Mission Statement
Corporate Overview
MacroGenics, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland. Founded in 2000, the company focuses on developing innovative monoclonal antibody-based therapeutics for cancer treatment.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $356.4 million |
| Net Loss | $292.1 million |
| Cash and Investments | $521.3 million |
| Research and Development Expenses | $373.2 million |
Key Research Areas
- Immunotherapies for oncology
- Bispecific antibody platforms
- Targeted cancer treatments
Clinical Pipeline
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| Pivekimab Sunirine | Metastatic Triple-Negative Breast Cancer | Phase 3 |
| Tebotelceote | Advanced Solid Tumors | Phase 2 |
| MGC018 | Solid Tumors | Phase 1 |
Strategic Objectives
MacroGenics aims to develop and commercialize novel therapeutic antibodies targeting cancer and other challenging diseases through innovative research and strategic partnerships.
Collaboration Partnerships
- Gilead Sciences
- Janssen Pharmaceuticals
- Synlogic
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | MGNX |
| Share Price (as of January 2024) | $6.43 |
| Market Capitalization | $524.1 million |
How MacroGenics, Inc. (MGNX) Works
Company Overview
MacroGenics, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland. As of Q4 2023, the company's market capitalization was approximately $654.3 million.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $276.4 million |
| Net Loss | $337.2 million |
| Research and Development Expenses | $413.6 million |
Product Pipeline
MacroGenics focuses on developing immunotherapies for cancer treatment.
- Margenza (margetuximab): HER2-targeted therapy for metastatic breast cancer
- Pivotal clinical trials for MGD015 in multiple cancer types
- Ongoing development of MGD230 immune checkpoint therapy
Key Therapeutic Areas
The company concentrates on developing immune-oncology therapies with a specific focus on:
- Breast cancer treatments
- Hematologic malignancies
- Solid tumor immunotherapies
Collaboration and Partnerships
| Partner | Agreement Details | Potential Milestone Payments |
|---|---|---|
| Gilead Sciences | Bispecific antibody collaboration | Up to $1.7 billion |
| Janssen Pharmaceuticals | Cancer immunotherapy research | Up to $1.2 billion |
Stock Performance
NASDAQ ticker MGNX traded at $4.87 as of January 2024, with annual volatility of 62.3%.
Operational Metrics
- Employees: 389 as of December 2023
- Research facilities: 2 primary locations in Maryland
- Active clinical trials: 7 ongoing programs
How MacroGenics, Inc. (MGNX) Makes Money
Revenue Streams
MacroGenics, Inc. generates revenue through multiple channels in the biopharmaceutical sector:
- Drug development and licensing agreements
- Collaboration partnerships
- Product sales
- Research grants
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $285.4 million |
| Collaboration Revenue | $252.1 million |
| Product Revenue | $33.3 million |
Key Collaboration Partnerships
MacroGenics maintains strategic partnerships with:
- Janssen Biotech
- Gilead Sciences
- Incyte Corporation
Product Portfolio
Primary Marketed Product: Margenza (margetuximab), a HER2-targeted therapy for metastatic breast cancer
| Product | 2023 Sales |
|---|---|
| Margenza | $33.3 million |
Research and Development Funding
MacroGenics invests significantly in R&D:
| R&D Expense Category | 2023 Amount |
|---|---|
| Total R&D Expenses | $373.1 million |
MacroGenics, Inc. (MGNX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.